I. Introduction: PET/CT Scans in Oncology

In the modern landscape of cancer diagnosis and management, the integration of anatomical and functional imaging has become paramount. Positron Emission Tomography combined with Computed Tomography (PET/CT) stands as a cornerstone of this integrated approach. This hybrid imaging modality provides a unique window into the metabolic activity of tissues, using a radioactive tracer, most commonly fluorodeoxyglucose (FDG), which is avidly taken up by metabolically active cancer cells. The CT component simultaneously delivers detailed anatomical mapping, allowing for precise localization of these hypermetabolic foci. This synergy makes ct pet scan an indispensable tool across the cancer care continuum—from initial diagnosis and staging to treatment response assessment and detection of recurrence.

The role of PET/CT extends beyond mere detection; it is pivotal for accurate staging, which directly informs prognosis and therapeutic strategy. By identifying distant metastases or unexpected sites of disease, PET/CT can upstage or downstage a patient, potentially shifting treatment from curative surgery to systemic therapy or vice versa. Its advantages over standalone modalities are significant. Compared to a standard mri or CT scan, PET/CT offers superior sensitivity and specificity for many cancers, reducing the number of indeterminate findings. While mri excels in soft tissue contrast and is superior for brain, spinal, and certain musculoskeletal evaluations, PET/CT provides a whole-body metabolic survey that mri cannot match in a single session. Compared to a standalone PET scan, the integrated CT provides the crucial anatomical context, improving diagnostic accuracy and speeding up interpretation. In Hong Kong, the adoption of PET/CT in public and private healthcare sectors has grown substantially. Data from the Hospital Authority shows a steady annual increase in PET/CT examinations, reflecting its established role in evidence-based oncology protocols.

II. Lung Cancer

Lung cancer, particularly non-small cell lung cancer (NSCLC), is a prime example where PET/CT has revolutionized management. For staging NSCLC, PET/CT is now the standard of care. It provides a comprehensive assessment of the primary tumor (T-stage), nodal involvement (N-stage), and distant metastases (M-stage) in a single examination. This is critical because the presence of mediastinal lymph node metastasis or distant disease drastically alters management, often precluding curative surgery. The metabolic information from PET helps differentiate between benign and malignant lymph nodes more accurately than CT size criteria alone, reducing the need for invasive mediastinoscopy in some cases.

In evaluating solitary pulmonary nodules, PET/CT plays a key role in risk stratification. Nodules with high FDG uptake are more likely to be malignant, guiding decisions for biopsy or surgical resection. However, it's important to note that some infections or inflammatory conditions can also cause FDG avidity, and certain slow-growing cancers (e.g., carcinoid, adenocarcinoma in situ) may not be FDG-avid. For monitoring treatment response, especially after chemotherapy, radiation, or targeted therapy, PET/CT is invaluable. A significant decrease in FDG uptake (metabolic response) often precedes anatomical shrinkage seen on CT and is a strong predictor of favorable outcome. This allows for early identification of non-responders, enabling a timely switch to alternative therapies.

III. Lymphoma

PET/CT with FDG has become the single most important imaging test for managing both Hodgkin lymphoma (HL) and most subtypes of non-Hodgkin lymphoma (NHL). For initial staging, it accurately defines the extent of nodal and extranodal disease, identifying sites that may be missed by conventional ct pet scan or mri. Its high sensitivity is particularly useful for detecting bone marrow involvement. The true power of PET/CT in lymphoma, however, lies in its ability to assess treatment response. The Deauville 5-point scale (or Lugano classification) is a standardized, internationally recognized system used to interpret post-treatment PET/CT scans. It compares the FDG uptake in residual tissue to reference backgrounds (like the liver and mediastinal blood pool).

• Score 1-2: No uptake or uptake ≤ mediastinal blood pool (Complete Metabolic Response).
• Score 3: Uptake > mediastinal blood pool but ≤ liver (Indeterminate/possible residual disease).
• Score 4-5: Uptake moderately or markedly higher than liver (Partial metabolic response or progressive disease).

This scoring system guides critical decisions, such as whether to continue chemotherapy, escalate treatment, or proceed to consolidative radiotherapy. For detecting recurrence in patients in remission, PET/CT is the most sensitive tool, often revealing metabolically active disease before symptoms appear or other imaging modalities show changes. In Hong Kong, lymphoma management protocols in major centers like Queen Mary Hospital rigorously incorporate Deauville criteria for response-adapted therapy.

IV. Melanoma

The use of PET/CT in melanoma is primarily reserved for patients with intermediate to high-risk primary tumors (e.g., deep invasion, ulceration) or those with clinical suspicion of regional or distant spread. For staging, it is not routinely used for early, thin melanomas but is crucial for Stage III (regional nodal metastasis) and Stage IV (distant metastasis) disease. PET/CT excels at identifying distant metastases to sites like the lung, liver, bone, distant lymph nodes, and even the small bowel—locations that can be challenging to assess comprehensively with other modalities. A whole-body ct pet scan can often replace multiple individual tests.

In the era of immunotherapy and targeted therapy (e.g., BRAF/MEK inhibitors), monitoring treatment response presents unique challenges. These agents can cause inflammatory responses (pseudoprogression) that mimic disease progression on anatomical imaging or even cause increased FDG uptake early in treatment. Serial PET/CT scans, interpreted with caution and in conjunction with clinical assessment, are essential to differentiate true progression from pseudoprogression. A baseline PET/CT before starting treatment and a follow-up scan after a few cycles can provide critical insights. While an mri remains superior for evaluating potential brain metastases (a common site in melanoma), PET/CT is the workhorse for systemic assessment. The metabolic information helps confirm the viability of residual masses after treatment, distinguishing scar tissue from active tumor.

V. Colorectal Cancer

In colorectal cancer (CRC), PET/CT is not a first-line tool for initial staging of early primary tumors, where endoscopic ultrasound and pelvic mri (for rectal cancer) are more precise for local T and N staging. Its major indications lie in three areas. First, for staging apparently localized but high-risk disease (e.g., T3/T4 tumors, high CEA levels) to rule out occult distant metastases, potentially altering surgical planning. Second, and most importantly, is in the detection of recurrence. CRC commonly recurs in the liver and lungs. PET/CT is highly sensitive and specific for detecting local pelvic recurrence and intra- and extra-hepatic metastases, especially when serum carcinoembryonic antigen (CEA) levels rise but conventional CT or mri findings are equivocal.

It can accurately characterize indeterminate liver lesions seen on other scans. Third, PET/CT is valuable for evaluating response to systemic therapy for metastatic disease and for assessing the resectability of metastatic lesions (e.g., in the liver) after neoadjuvant chemotherapy. A complete metabolic response on PET/CT in liver metastases is a favorable prognostic sign. In Hong Kong, with CRC being one of the most common cancers, PET/CT is a frequently utilized tool in multidisciplinary team meetings at centers like the Hong Kong Sanatorium & Hospital to plan curative-intent surgeries for oligometastatic disease or to guide palliative systemic therapy.

VI. Breast Cancer

The role of PET/CT in breast cancer is selective. It is not recommended for early-stage, potentially curable breast cancer (Stage I/II) due to its low yield and high cost. Its primary utility is in staging locally advanced (Stage III) or metastatic (Stage IV) breast cancer. For these patients, a whole-body PET/CT can efficiently detect unsuspected bone, nodal, or visceral metastases, providing a more accurate picture of disease burden than the traditional combination of bone scan and CT chest/abdomen/pelvis. This accurate staging is crucial for determining whether treatment should be with curative or palliative intent.

A key and well-validated application is assessing response to neoadjuvant chemotherapy (NAC) given before surgery for locally advanced breast cancer. A mid-treatment PET/CT can identify responders from non-responders early in the course of therapy. Patients showing a significant metabolic response are more likely to achieve a pathological complete response (pCR) at surgery, which is associated with excellent long-term outcomes. Non-responders can be considered for a switch in chemotherapy regimen. For detecting recurrence, PET/CT is highly effective, particularly in patients with rising tumor markers (like CA15-3) and negative or ambiguous findings on conventional imaging like mammography, ultrasound, or even a dedicated breast mri. It can pinpoint the site of recurrence, whether locoregional or distant.

VII. Other Cancers

The utility of PET/CT extends to several other malignancies, each with specific indications. In Head and neck cancer, it is vital for initial staging to detect occult primary tumors in patients presenting with metastatic cervical lymph nodes, for accurate nodal staging, and for detecting distant metastases. It is also the preferred modality for detecting recurrence and assessing response after chemoradiation, where post-treatment anatomical changes on CT or mri make interpretation difficult.

For Esophageal cancer, PET/CT is standard for initial staging to evaluate for distant metastatic disease and for nodal staging, though endoscopic ultrasound remains superior for local T-stage. Its most critical role is in assessing response to neoadjuvant chemoradiation before planned surgery. A lack of metabolic response on post-treatment PET/CT may indicate a need for treatment modification.

In Thyroid cancer, specifically differentiated thyroid cancer (DTC) like papillary and follicular types, a specialized form of PET/CT using radioactive iodine (I-131 or I-124) is the standard for staging and treatment. However, FDG PET/CT has a crucial niche in managing patients with elevated thyroglobulin levels and negative radioiodine whole-body scans—a scenario indicating dedifferentiation of the cancer cells. In these cases, FDG PET/CT can locate iodine-negative, FDG-avid metastatic disease, guiding further management. It's important to distinguish this from a standard chụp mri (the Vietnamese term for MRI scan), which might be used for local soft tissue assessment in the neck but does not provide this whole-body metabolic information.

VIII. Conclusion: The evolving role of PET/CT in personalized cancer care

The journey of PET/CT in oncology is one of continuous evolution and integration into personalized treatment paradigms. From its established roles in staging and response assessment in common cancers like lung cancer and lymphoma, to its selective but critical applications in melanoma, colorectal, and breast cancers, PET/CT has proven to be a transformative technology. Its ability to provide a quantitative measure of tumor metabolism is increasingly being leveraged beyond qualitative assessment. Parameters like Standardized Uptake Value (SUV) and metabolic tumor volume are being studied as prognostic biomarkers and for radiotherapy planning. The future points towards the development of novel tracers beyond FDG that target specific biological processes (e.g., prostate-specific membrane antigen (PSMA) for prostate cancer, somatostatin receptors for neuroendocrine tumors), further expanding the molecular precision of PET/CT. As artificial intelligence aids in image analysis, the efficiency and accuracy of interpretation will improve. In essence, PET/CT has moved from being a mere diagnostic tool to an integral component of the therapeutic decision-making engine, enabling truly personalized and adaptive cancer care strategies that aim to maximize efficacy while minimizing unnecessary treatment and its associated toxicities.